LexisNexis® Legal Newsroom
2 Attorneys Settle Their Avandia Cases In Federal, State Courts

PHILADELPHIA — (Mealey’s) Two attorneys have settled their Avandia personal injury cases in federal and state courts with defendant GlaxoSmithKline plc, a source told Mealey Publications May 10. According to the source, W. Mark Lanier of the Lanier Law Firm in Houston and Sol Weiss of...

Most FDA Advisers Recommend Avandia Stay On The Market

GAITHERSBURG, Md. - (Mealey's) A majority of Food and Drug Administration advisers voted July 14 to keep Avandia on the market but split on whether the anti-diabetes drug made by GlaxoSmithKline PLC (GSK) should carry additional warnings about its heart risks or that its use be restricted. Twelve...

A Word Change Here And There and Voila! GlaxoSmithKline Has Itself 33 New Avandia Experts

So you saw the words "$2.36 billion," "settlement," and "Avandia" used in the same sentence and you think the litigation is over? Well, the old gal's still kicking and nowhere was that more apparent that in GSK's Aug. 9 "overview memorandum" trying to...

Avandia Off Market In Europe; FDA To Restrict Its Use, Orders Probe of GSK Study

(Mealey's) The European Medicines Agency (EMA) on Sept. 23 recommended that the marketing authorization for GlaxoSmithKline PLC's (GSK) controversial anti-diabetes drug Avandia be suspended, and the Food and Drug Administration simultaneously said it will significantly restrict Avandia use in...

Glaxo Adds Safety Restrictions To Avandia Label

WASHINGTON, D.C. - (AP) GlaxoSmithKline PLC said Monday it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack. The Food and Drug Administration announced the changes in September as...

Lawsuits Follow Diabetes Drug Actos' Link To Cancer Risk

TRENTON, N.J. - (AP) The maker of the world's best-selling diabetes drug is facing hundreds of lawsuits and likely a big sales drop as suspicion grows that taking the pill for more than a year raises the risk of bladder cancer. In June, Takeda Pharmaceuticals Co. Ltd. halted sales of Actos. . . ...